WO2001024784A3 - New use - Google Patents

New use Download PDF

Info

Publication number
WO2001024784A3
WO2001024784A3 PCT/JP2000/006874 JP0006874W WO0124784A3 WO 2001024784 A3 WO2001024784 A3 WO 2001024784A3 JP 0006874 W JP0006874 W JP 0006874W WO 0124784 A3 WO0124784 A3 WO 0124784A3
Authority
WO
WIPO (PCT)
Prior art keywords
new use
inhibitor
increasing
plasminogen activator
effect caused
Prior art date
Application number
PCT/JP2000/006874
Other languages
French (fr)
Other versions
WO2001024784A2 (en
Inventor
Akira Moriguchi
Yasuhisa Furuichi
Kiyotaka Katsuta
Masashi Maeda
Natsuki Sato
Original Assignee
Fujisawa Pharmaceutical Co
Akira Moriguchi
Yasuhisa Furuichi
Kiyotaka Katsuta
Masashi Maeda
Natsuki Sato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ3249A external-priority patent/AUPQ324999A0/en
Priority claimed from AUPQ5643A external-priority patent/AUPQ564300A0/en
Application filed by Fujisawa Pharmaceutical Co, Akira Moriguchi, Yasuhisa Furuichi, Kiyotaka Katsuta, Masashi Maeda, Natsuki Sato filed Critical Fujisawa Pharmaceutical Co
Priority to EP00963073A priority Critical patent/EP1223969A2/en
Priority to JP2001527783A priority patent/JP2003510351A/en
Publication of WO2001024784A2 publication Critical patent/WO2001024784A2/en
Publication of WO2001024784A3 publication Critical patent/WO2001024784A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is related to a new use of a plasminogen activator, for increasing an effect caused by IL-2 inhibitor and, further, a use of IL-2 inhibitor for increasing or decreasing an effect caused by plasminogen activator.
PCT/JP2000/006874 1999-10-04 2000-10-02 New use WO2001024784A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00963073A EP1223969A2 (en) 1999-10-04 2000-10-02 Combined use of a plasminogen activator and il-2 inhibitors for neuroprotection
JP2001527783A JP2003510351A (en) 1999-10-04 2000-10-02 New applications

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ3249 1999-10-04
AUPQ3249A AUPQ324999A0 (en) 1999-10-04 1999-10-04 New use
AUPQ5643 2000-02-15
AUPQ5643A AUPQ564300A0 (en) 2000-02-15 2000-02-15 New use

Publications (2)

Publication Number Publication Date
WO2001024784A2 WO2001024784A2 (en) 2001-04-12
WO2001024784A3 true WO2001024784A3 (en) 2002-05-10

Family

ID=25646165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/006874 WO2001024784A2 (en) 1999-10-04 2000-10-02 New use

Country Status (3)

Country Link
EP (1) EP1223969A2 (en)
JP (1) JP2003510351A (en)
WO (1) WO2001024784A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078555A1 (en) * 2002-03-29 2006-04-13 Johns Hopkins University Intraventricular hemorrhage thrombolysis
CA2954043A1 (en) 2014-07-24 2016-01-28 Litevax B.V. Carbohydrate ester adjuvants
WO2020228681A1 (en) * 2019-05-10 2020-11-19 泰伦基国际有限公司 Method and medicine for treating amyotrophic lateral sclerosis
KR20220158036A (en) * 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 Methods and drugs for the treatment of Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648351A (en) * 1992-12-29 1997-07-15 Fujisawa Pharmaceutical Co., Ltd. Use of macrolides for the treatment of cerebral ischemia
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648351A (en) * 1992-12-29 1997-07-15 Fujisawa Pharmaceutical Co., Ltd. Use of macrolides for the treatment of cerebral ischemia
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEDNAR M M ET AL: "COMBINATION TISSUE PLASMINOGEN ACTIVATOR AND TICLOPIDINE THERAPY INA RABBIT MODEL OF ACUTE THROMBOEMBOLIC STROKE", NEUROLOGICAL RESEARCH,XX,XX, vol. 18, no. 1, 1 February 1996 (1996-02-01), pages 45 - 48, XP000646532 *
BOCHELEN D ET AL: "CALCINEURIN INHIBITORS FK506 AND SDZ ASM 981 ALLEVIATE THE OUTCOME OF FOCAL CEREBRAL ISCHEMIC/REPERFUSION INJURY", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,AMERICAN SOCIETY FOR PHARMACOLOGY AND,US, vol. 288, no. 2, February 1999 (1999-02-01), pages 653 - 659, XP000980203, ISSN: 0022-3565 *
BUNDICK ET AL: "FK506 AS AN AGONIST TO INDUCE INHIBITION OF INTERLEUKIN 2 PRODUCTION", TRANSPLANTATION,US,WILLIAMS AND WILKINS, BALTIMORE, MD, vol. 53, no. 5, 1992, pages 1150 - 1153, XP000913592, ISSN: 0041-1337 *
KIM YANG-HEE ET AL: "Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.", SCIENCE (WASHINGTON D C), vol. 284, no. 5414, 23 April 1999 (1999-04-23), pages 647 - 650, XP002164663, ISSN: 0036-8075 *
MAEDA MASASHI ET AL: "FK506 (tacrolimus) as a potential anti-stroke agent (3): Increased therapeutic efficacy with combined treatment of FK506 and recombinant tissue plasminogen activator (rt-PA) in a rat stroke model.", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. Suppl. 1, 2000, 73rd Annual Meeting of the Japanese Pharmacological Society.;Yokohama, Japan; March 23-25, 2000, pages 174P, XP000990982, ISSN: 0021-5198 *
TOUNG THOMAS J ET AL: "Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats.", STROKE, vol. 30, no. 6, June 1999 (1999-06-01), pages 1279 - 1285, XP000980399, ISSN: 0039-2499 *
YAGITA Y ET AL: "EFFECT OF IMMUNOSUPRESSANT FK506 ON ISCHEMIA-INDUCED DEGENERATION OF HIPPOCAMPAL NEURONS IN GERBILS", LIFE SCIENCES,PERGAMON PRESS, OXFORD,GB, vol. 59, no. 19, 1996, pages 1643 - 1650, XP000980211, ISSN: 0024-3205 *

Also Published As

Publication number Publication date
JP2003510351A (en) 2003-03-18
WO2001024784A2 (en) 2001-04-12
EP1223969A2 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
BR0317715A (en) Compositions and processes of use of collajolie
AU2002357882A1 (en) Small-molecule inhibitors of interleukin-2
MXPA03010909A (en) Epothilone derivatives.
AU1624801A (en) Plasminogen activator inhibitor antagonists related applications
YU5503A (en) Non-steroidal inflammation inhibitors
AU2002251266A1 (en) Inhibitors of akt activity
PT1413582E (en) PYRROLOBENZODIAZEPINAS DIMERICAS
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
WO2001094347A8 (en) Tetracyclic diketopiperazine compounds as pdev inhibitors
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU1930900A (en) Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
AU5628800A (en) Substituted benzamide inhibitors of rhinovirus 3c protease
AU2001259990A1 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
WO2001024784A3 (en) New use
AU2003264688A1 (en) Steel hollow-head screw
EP1476149A4 (en) Substituted hydrazones as inhibitors of cyclooxygenase-2
AU2003274565A1 (en) Composition for the treatment of nasopharyngeal carcinoma and use thereof
AU1142502A (en) Novel crystalline forms of a factor xa inhibitor
PT1042288E (en) Tripeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000963073

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 527783

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10088502

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000963073

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000963073

Country of ref document: EP